|
KMID : 1141720220100020054
|
|
폐쇄성폐질환
2022 Volume.10 No. 2 p.54 ~ p.59
|
|
|
New treatment of COPD beyond LAMA/LABA and ICS
|
|
Shin Sun-Hye
|
|
|
Abstract
|
|
|
|
Current maintenance pharmacotherapies for chronic obstructive pulmonary disease (COPD) are mostly confined to inhaled bronchodilators (long-acting muscarinic antagonist [LAMA] and/or long-acting beta-2 agonist [LABA]) and corticosteroids. For some patients who experience frequent exacerbation despite these treatment, additional agent such as roflumilast, an orally administered phosphodiesterase (PDE) 4 inhibitor, or long-term azithromycin, a macrolide antibiotic, could be used to reduce the risk of exacerbation. There have been continued attempts to develop drugs beyond bronchodilators and corticosteroid. However, many of those approaches have failed to reach the clinical practice. This article will firstly review the established pharmacologic therapies: roflumilast and long-term azithromycin. Next, among various novel agents that have been studied in recent years, inhaled dual PDE 3/4 inhibitor (ensifentrine) and the biological agents targeting type 2 inflammations (mepolizumab, benralizumab, and itepekimab) will be introduced.
|
|
|
KEYWORD
|
|
|
biologics, chronic obstructive pulmonary disease, macrolide, pharmacotherapy, phosphodiesterase inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|